Alzheimer's disease
| 4 min read
Neuroscience discoveries, pharma investments, FOIA requests, and more led the news this week.
| 4 min read
Alzheimer’s diagnosis tests, AI-designed DNA circuits, bacterial insights, and more led the news this week.
| 4 min read
Novel Alzheimer’s screening tests, promising weight loss drug data, an AI model linking sleep to disease risk, and more led the news this week.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 7 min read
While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease.
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 4 min read
Big-ticket licensing, FDA shake-ups, and Alzheimer’s data led the news this week.
| 2 min read
Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches
| 10 min read
Learn about the latest advances in age-related macular degeneration (AMD) treatment, including a new drug that targets beta-amyloid to help prevent blindness and vision loss.
